Health CarePharmaceuticals and Biotechnology
  • Price (EUR)3.48
  • Today's Change-0.06 / -1.69%
  • Shares traded204.42k
  • 1 Year change-74.05%
  • Beta1.7261
Data delayed at least 15 minutes, as of May 23 2022 16:35 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

  • Revenue in EUR (TTM)40.66m
  • Net income in EUR-127.12m
  • Incorporated2000
  • Employees345.00
  • Location
    Cellectis SA8, rue de la Croix JarryPARIS 75013FranceFRA
  • Phone+33 181691600
  • Fax+33 181691606
  • Websitehttp://www.cellectis.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Gensight Biologics SA5.28m-28.62m96.55m38.00--6.08--18.30-0.6338-0.63380.11860.34530.1015--13.09138,842.10-55.03-63.75-88.54-83.23-----542.40-1,456.76---15.630.5226--20.07--15.87---29.91--
Eurofins-Cerep SA41.62m9.84m102.90m197.0010.452.279.212.471,951.381,951.388,257.309,003.020.78682.416.40211,252.7018.6114.1523.2117.7786.2959.0123.6517.723.7013.880.0623--27.4012.1776.4831.68----
Maat Pharma SA972.00k-9.02m109.74m33.00--2.75--112.90-0.9103-0.91030.09834.03------29,454.54--------43.31---927.88--10.04-73.500.1272-------70.14------
Ose Immunotherapeutics SA26.31m-16.85m126.73m61.00--2.64--4.82-0.9309-0.93091.452.590.2646--28.50431,245.90-16.95-9.88-20.06-11.76-----64.05-45.90---20.470.4367--152.17133.01-1.78--73.53--
Pcas SA187.01m-40.48m132.04m1.17k--4.31--0.706-2.95-2.9513.612.020.63661.729.23159,701.10-13.78-4.98-32.54-8.4934.6541.29-21.64-6.530.314-12.550.7172---3.66-0.5247-170.81--12.84--
Biocorp Production SA10.23m294.23k139.59m67.00473.16----13.650.06760.06762.35------------------95.9193.832.88-38.40--1.53----20.9228.22123.68------
Medincell SA8.56m-20.02m147.34m150.00------17.21-0.8369-0.83690.3599-0.06550.1782--17.9557,858.11-41.67---55.20--83.23---233.84--2.84-15.031.04--187.03--20.47------
Groupe Berkem SA-100.00bn-100.00bn155.45m164.00--5,185.17----------0.0017------------------------1.05--0.5806--13.54---62.94------
Cellectis SA40.66m-127.12m161.38m345.00--0.8922--3.97-2.81-2.810.90063.980.1087--3.04117,855.20-36.59-24.90-44.41-30.71---29.56-336.58-232.72----0.3221---18.663.51-40.86---18.03--
DBV Technologies SA5.41m-92.85m165.47m226.00------30.61-1.70-1.700.0987-----------------------1,717.80-1,272.93---586.89-----49.38-10.6938.59------
Genfit SA85.58m67.26m168.97m122.003.171.422.411.971.071.071.542.390.3563367.7521.32--28.01-18.6734.81-21.8298.2893.3978.59-157.664.27--0.3735--1,003.1166.03166.45---23.40--
Biosynex SA153.90m31.37m176.81m200.005.682.395.381.153.053.0516.817.241.784.1921.50769,476.9037.2313.9954.8018.1245.0448.5720.9412.311.12--0.19225.51349.5973.212,711.82------
Nanobiotix SA10.00k-47.00m179.01m100.00--6.68--17,900.50-1.35-1.350.00030.76960.00008--0.3226100.00-39.87-52.22-52.25-66.48-----470,040.00-37,902.42----0.6159---80.00-63.57-39.93------
Eurobio Scientific SA222.34m80.86m224.14m168.002.771.682.541.017.147.1419.3911.741.496.475.83--54.30--70.99--60.5850.5136.3723.244.1897.930.1183---2.2046.13-17.67------
Innate Pharma SA12.11m-45.48m231.76m215.00--2.15--19.14-0.572-0.66340.15231.350.0421--2.1256,334.88-15.82-6.65-20.23-9.5874.6992.81-375.48-45.00----0.4407---78.43-26.42-5,385.89---32.35--
Transgene SA17.01m-19.54m232.94m167.00--3.40--13.69-0.219-0.2190.18670.68740.1817--2.88101,880.20-20.86-15.27-24.56-18.27-----114.82-147.28----0.0541--82.1014.28-13.38--90.14--
Data as of May 23 2022. Currency figures normalised to Cellectis SA's reporting currency: Euro EUR

Institutional shareholders

14.87%Per cent of shares held by top holders
HolderShares% Held
Baillie Gifford & Co.as of 31 Dec 20213.26m7.16%
Capital Research & Management Co. (World Investors)as of 31 Mar 20221.08m2.37%
Capital Research & Management Co. (International Investors)as of 31 Dec 2021581.75k1.28%
Norges Bank Investment Managementas of 31 Dec 2021519.00k1.14%
BlackRock Fund Advisorsas of 04 May 2022417.56k0.92%
Bessemer Investment Management LLCas of 31 Jan 2022389.06k0.86%
KBC Fund Management Ltd.as of 31 Dec 2021163.45k0.36%
JPMorgan Asset Management (UK) Ltd.as of 30 Nov 2021160.13k0.35%
Financi�re Arbevel SAas of 30 Jun 2021110.00k0.24%
Saint Olive Gestion SNCas of 31 Jan 202185.00k0.19%
More ▼
Data from 31 Jan 2021 - 31 Mar 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.